Alaunos Therapeutics, Inc. (TCRT) Stock Price & How to Invest
Last updated July 2026
Short answer
You can invest in Alaunos Therapeutics (TCRT) by buying shares or fractional shares at any major US broker, though it is an extremely small, high-risk nano-cap that trades on Nasdaq. Alaunos, formerly Ziopharm Oncology, was a cancer cell-therapy company that has pivoted to a preclinical obesity and metabolic-disorders program built around an oral, non-hormonal small molecule called ALN1003. The single most important thing to understand is that this is a pre-revenue, cash-strapped biotech: as of March 31, 2026 it reported only about $0.35 million in cash, has received a Nasdaq listing-deficiency notice, and has warned its runway extends only into 2026, so the shares carry severe going-concern and delisting risk and could lose most or all of their value.
TCRT stock price
As of 2026-07-14, Alaunos Therapeutics, Inc. (TCRT) last closed at $2.06, down 48.5% over the past year. Over the past 52 weeks it has traded between $1.77 and $4.36.
Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or Alaunos Therapeutics, Inc.'s investor relations page. Walnut is informational, not investment advice.
What does Alaunos Therapeutics, Inc. (TCRT) do?
Alaunos Therapeutics, formerly Ziopharm Oncology, spent years as a clinical-stage cancer cell-therapy company developing T-cell receptor (TCR-T) therapies for solid tumors. In 2023 it wound down its sole clinical study and cut most of its workforce, prioritizing its hunTR neoantigen-TCR discovery platform and exploring strategic alternatives. By 2026 the company had pivoted again, repositioning itself as a preclinical obesity and metabolic-disorders company centered on ALN1003, an oral small-molecule candidate that it describes as a non-hormonal, non-incretin approach (different from GLP-1 drugs). It has reported early preclinical, animal-model data suggesting weight and metabolic effects, but the program is pre-human, so there is no clinical proof of safety or efficacy in people, and no product revenue.
The financial situation is precarious. As of March 31, 2026 the company reported only about $0.35 million in cash and cash equivalents, with management estimating the runway extends into the second quarter of 2026, a classic going-concern setup that will require new financing to continue operating. In April 2026 Alaunos received a notice from Nasdaq that it no longer met the minimum stockholders' equity requirement of $2.5 million under Listing Rule 5550(b)(1), putting it at risk of delisting, and it was given a deadline to submit a remediation plan. A group of shareholders separately proposed a roughly $7 million private-placement financing that, if completed, would result in a change of control. The share count is very small and heavy dilution is likely if the company raises capital, so TCRT is best understood as a survival-and-financing story, not a business valued on fundamentals.
What's driving Alaunos Therapeutics, Inc. (TCRT)?
1. Obesity and metabolic pivot (ALN1003)
The entire forward story now rests on ALN1003, an oral small-molecule candidate for obesity and related metabolic disorders. Alaunos has reported early preclinical, animal-model data pointing to weight loss and metabolic improvements. Obesity is one of the largest drug markets in the world, so even a small preclinical program can attract speculative interest. But the candidate is pre-human, and the vast majority of preclinical drugs never reach or succeed in clinical trials.
2. Non-hormonal, non-incretin differentiation
Alaunos frames ALN1003 as a non-hormonal, non-incretin mechanism, distinct from the GLP-1 receptor agonists (like semaglutide and tirzepatide) that dominate the current obesity market. If that differentiation held up in human trials, it could in theory address tolerability or access gaps that injectable incretin drugs leave open. This is a hypothesis, not a demonstrated advantage, and it would take years and substantial funding to test in people.
3. Legacy hunTR discovery platform
The company retains its hunTR neoantigen-TCR discovery platform from its cancer-therapy era, which it has used to screen large numbers of TCR-neoantigen combinations. This intellectual property could hold value in a partnership or licensing deal, but the company is no longer prioritizing clinical cancer development, so the platform's near-term contribution to value is uncertain and largely optionality rather than an active program.
4. Financing and strategic alternatives
With cash nearly exhausted, the most immediate driver is whether Alaunos can raise money or complete a strategic transaction. A shareholder group proposed a roughly $7 million private placement that would trigger a change of control, and the company has said it continues to explore alternatives including capital raises, partnerships, or a reverse merger. Any of these could keep the company alive, but most likely on terms that heavily dilute or displace existing shareholders.
What are the risks to Alaunos Therapeutics, Inc. (TCRT)?
The risks here are severe and existential, and outweigh the typical risks of a normal stock. Alaunos is a pre-revenue nano-cap with roughly $0.35 million in cash as of March 2026 and a runway management estimated only into the second quarter of 2026, so it faces going-concern doubt and needs new financing simply to keep operating. It has received a Nasdaq deficiency notice for failing the minimum stockholders' equity requirement and is at genuine risk of delisting, which would further hurt liquidity and value. Its lead program, ALN1003, is preclinical with no human data, in an obesity market dominated by Novo Nordisk and Eli Lilly. Any capital raise is likely to be highly dilutive, and a proposed financing would result in a change of control. The stock is thinly traded and extremely volatile, and there is a real possibility that shareholders lose most or all of their investment.
How is Alaunos Therapeutics, Inc. (TCRT) valued? (approximate, Jul 2026)
A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Alaunos Therapeutics, Inc.'s investor relations page or your broker.
- Revenue trend: No product revenue; the company is preclinical with its lead obesity candidate. Any income is incidental, not from product sales.
- Profitability: Deeply unprofitable, as expected for a preclinical biotech; ongoing net losses and cash burn with no near-term path to earnings.
- Balance sheet: About $0.35 million in cash as of March 31, 2026, with runway estimated only into Q2 2026 and going-concern risk. Verify the latest cash position, which can change quickly.
- Nasdaq listing status: Received an April 2026 deficiency notice for failing the $2.5 million minimum stockholders' equity rule; at risk of delisting pending a remediation plan.
- Market cap tier: Nano-cap, in the low single-digit millions of dollars and highly volatile. Approximate; verify live given how fast it can move.
- Analyst coverage: Minimal to none; the stock trades on financing news and speculation rather than institutional research or fundamentals.
All figures are approximate and tied to the asOf date; verify live numbers before acting, because a company in this condition can change rapidly through dilution, a reverse split, a financing, or delisting. Traditional valuation is not meaningful here: with no revenue, near-zero cash, and going-concern and delisting risk, the stock is priced on survival odds and speculation, not on earnings or assets. A very low share price does not make it cheap.
Who competes with Alaunos Therapeutics, Inc. (TCRT)?
Obesity and metabolic pharma leaders
Novo Nordisk and Eli Lilly dominate the obesity and metabolic market with their GLP-1 and dual-agonist franchises (semaglutide, tirzepatide). They have approved products, massive R&D budgets, and manufacturing scale that a preclinical nano-cap like Alaunos cannot match. They define the bar ALN1003 would eventually have to clear or differentiate against.
Emerging oral and non-incretin obesity biotechs
A wave of smaller and mid-size biotechs, including names like Structure Therapeutics, Viking Therapeutics, and others pursuing oral or novel-mechanism obesity drugs, are the closest peer set for the ALN1003 thesis. Most are far better funded and further along (in human trials), which underscores how early and under-resourced Alaunos is by comparison.
Legacy cell-therapy and neoantigen-TCR players
From its former cancer-therapy identity, Alaunos sits alongside TCR and cell-therapy developers such as Adaptimmune and other neoantigen-focused biotechs. Its hunTR platform relates to this field, but since the company has deprioritized clinical cancer work, these are more historical peers than active competitors today.
How to invest in Alaunos Therapeutics, Inc. (TCRT)
There are three common ways to get TCRT exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic basket, so TCRT sits alongside other stocks that express the same thesis.
Walnut takes the basket route. Describe a thesis where TCRT fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.
The bottom line on Alaunos Therapeutics, Inc. (TCRT)
Alaunos is a pre-revenue, nearly out-of-cash nano-cap biotech that pivoted from cancer cell therapy to a preclinical obesity drug. With about $0.35 million in cash, a Nasdaq deficiency notice, and going-concern risk, it is a highly speculative bet on raising money and delivering early data, not a stable investment.
Build a basket around TCRT with Walnut
Use Alaunos Therapeutics, Inc. as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
Is TCRT a good stock to buy right now?
+
That depends on your goals and risk tolerance, and this is not investment advice, but you should understand the risk is extreme. Alaunos is a pre-revenue nano-cap with roughly $0.35 million in cash as of March 2026, a going-concern warning, a Nasdaq delisting notice, and only a preclinical obesity drug candidate. It is a highly speculative bet on the company raising money and surviving, and there is a real possibility of losing most or all of an investment. Weigh that carefully against your portfolio.
Is TCRT still listed on Nasdaq?
+
As of mid-2026 Alaunos still traded on Nasdaq under the ticker TCRT, but it received an April 2026 notice that it no longer met the minimum stockholders' equity requirement under Listing Rule 5550(b)(1) and was at risk of delisting. It was given a deadline to submit a remediation plan. Listing status can change, so confirm the current situation before assuming the stock remains on Nasdaq.
What does Alaunos Therapeutics do now?
+
Alaunos, formerly Ziopharm Oncology, was a cancer cell-therapy company that wound down its clinical study in 2023 and has since pivoted to a preclinical obesity and metabolic-disorders program centered on ALN1003, an oral small-molecule candidate. It has no approved products and no product revenue, and its lead program is still in preclinical (animal-model) stages.
What is ALN1003?
+
ALN1003 is Alaunos's lead drug candidate, an oral small molecule for obesity and related metabolic disorders that the company describes as a non-hormonal, non-incretin approach, meaning it works differently from GLP-1 drugs. As of 2026 the company had reported early preclinical data in animal models. It has not been tested in humans, so its safety and efficacy in people are unproven.
Why is TCRT so cheap and volatile?
+
TCRT is a nano-cap with almost no cash, going-concern doubt, and a delisting risk, so the market prices it as a speculative survival story rather than on fundamentals. Its very small share count and thin trading mean the price can swing violently on financing news, dilution, or rumors. A low absolute price does not mean it is a bargain; it reflects the severe risk of loss.
Does Alaunos have enough money to keep operating?
+
As of March 31, 2026 the company reported only about $0.35 million in cash and estimated its runway extended only into the second quarter of 2026. That is a classic going-concern situation, meaning it needs new financing to continue operating. A shareholder group proposed a roughly $7 million private placement that would result in a change of control, but there is no guarantee any financing closes.
Was TCRT a meme stock?
+
TCRT, especially in its former Ziopharm Oncology identity, has at times attracted speculative retail interest given its low price and biotech story. Regardless of any meme dynamics, the stock today is defined by its near-empty balance sheet, delisting risk, and preclinical pipeline, which make it inherently high-risk and prone to sharp, sentiment-driven moves.
What could go right for Alaunos?
+
The bull case would require the company to secure meaningful financing or a strategic transaction to survive, resolve its Nasdaq listing deficiency, and generate encouraging early data for ALN1003 that supports advancing into human trials. Even in a good scenario, any capital raise is likely to be dilutive, and the obesity market is dominated by far larger players, so success is far from assured.
What are the main risks of investing in TCRT?
+
The risks are existential: near-zero cash and going-concern doubt, a Nasdaq delisting notice, a preclinical-only pipeline with no human data, and an obesity market dominated by Novo Nordisk and Eli Lilly. Any financing is likely highly dilutive, a proposed deal would trigger a change of control, and the stock is thinly traded and extremely volatile. Shareholders face a real possibility of losing most or all of their investment.
Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with Alaunos Therapeutics, Inc.'s investor relations page or your broker before making investment decisions.